Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Biomarker and diagnostic research for xanthogranuloma has been reported in the published literature.
5 clinical trials registered, 4 recruiting. Interventions under study include drug therapy, other interventions, and procedural interventions. Pipeline includes 3 PHASE2. Research is primarily sponsored by academic and government institutions.
NCT ID | Title | Phase | Sponsor | Status |
|---|---|---|---|---|
[NCT05915208](https://clinicaltrials.gov/study/NCT05915208) |
Data assembled from 3 of 12 sources · Last updated Sep 20, 2026, 1:11 PM UTC
Histiocytic Disorder Follow-up Study |
— |
University of Alabama at Birmingham |
RECRUITING |
[NCT04079179](https://clinicaltrials.gov/study/NCT04079179) | Cobimetinib in Refractory Langerhans Cell Histiocytosis (LCH), and Other Histiocytic Disorders | PHASE2 | Carl Allen | RECRUITING |
[NCT02285582](https://clinicaltrials.gov/study/NCT02285582) | International Rare Histiocytic Disorders Registry (IRHDR) | — | The Hospital for Sick Children | RECRUITING |
[NCT06153173](https://clinicaltrials.gov/study/NCT06153173) | Mirdametinib in Histiocytic Disorders | PHASE2 | Children's Hospital Medical Center, Cincinnati | RECRUITING |
[NCT03155620](https://clinicaltrials.gov/study/NCT03155620) | Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial) | PHASE2 | National Cancer Institute (NCI) | ACTIVE_NOT_RECRUITING |
178 publications have been identified in PubMed for xanthogranuloma. Research spans Case Report / Case Series (53%), Review / Meta-Analysis (18%), and Other (15%).
Research Type | Count | % of Total |
|---|---|---|
Patient case studies | 95 | 53% |
Research summaries | 32 | 18% |
Other research | 26 | 15% |
Testing and diagnosis research | 10 | 6% |
Laboratory research | 9 | 5% |
Disease patterns and progression | 3 | 2% |
New treatment approaches | 3 | 2% |
Syed HA (2026). [PMID: 30252359](https://pubmed.ncbi.nlm.nih.gov/30252359/). *Unknown Journal*. [Case Report / Case Series]
Methaprayoon W (2026). [PMID: 41545221](https://pubmed.ncbi.nlm.nih.gov/41545221/). *BMJ Case Rep*. [Case Report / Case Series]
Ondič O (2026). [PMID: 42024164](https://pubmed.ncbi.nlm.nih.gov/42024164/). *Virchows Arch*. [Case Report / Case Series]
Jüttner E (2026). [PMID: 41603897](https://pubmed.ncbi.nlm.nih.gov/41603897/). *Pathologie (Heidelb)*. [Review / Meta-Analysis]
Däniker M (2026). [PMID: 41170802](https://pubmed.ncbi.nlm.nih.gov/41170802/). *Pediatr Dev Pathol*. [Review / Meta-Analysis]
Talasila S (2026). [PMID: 41799352](https://pubmed.ncbi.nlm.nih.gov/41799352/). *JAAD Case Rep*. [Case Report / Case Series]
Ferraz R (2026). [PMID: 41842676](https://pubmed.ncbi.nlm.nih.gov/41842676/). *Arch Argent Pediatr*. [Case Report / Case Series]
Long X (2026). [PMID: 41655091](https://pubmed.ncbi.nlm.nih.gov/41655091/). *Indian J Dermatol Venereol Leprol*. [Other]
Mir TH (2026). [PMID: 41740896](https://pubmed.ncbi.nlm.nih.gov/41740896/). *J Am Acad Dermatol*. [Other]
Strickland T (2026). [PMID: 41487543](https://pubmed.ncbi.nlm.nih.gov/41487543/). *Proc (Bayl Univ Med Cent)*. [Case Report / Case Series]